SAN FRANCISCO—Intravesical gemcitabine may be a safe and effective treatment for superficial bladder cancer, data suggest.

SAN FRANCISCO—Statin use may decrease the likelihood that superficial bladder cancer will progress to muscle-invasive disease requiring cystectomy, according to researchers at the University Hospital of Montreal in Canada.

ELEVATED C-reactive protein (CRP) levels before chemoradiotherapy for muscle-invasive bladder cancer is associated with a poor prognosis, according to researchers at Tokyo Medical and Dental University in Japan.

TRANSITIONAL CELL carcinoma (TCC) is the predominant malignancy to develop in Chinese renal transplant recipients, according to researchers at the Capital University of Medical Sciences in Beijing.

Indevus Pharmaceuticals, Inc., of Lexington, Mass., has received a non-approvable letter from the FDA for Valstar (valrubicin solution), the only approved product for therapy of bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder.

Indevus Pharmaceuticals, Inc., of Lexington, Mass., announced that it has received a non-approvable letter from the FDA for Valstar (valrubicin solution), the only approved product for therapy of bacillus Calmette-Guérin-refractory carcinoma in situ of the urinary bladder.

A terminally ill Illinois man has won a $1.6 million verdict against the general practitioner who failed to diagnose bladder cancer.

One third of the standard dose of bacillus Calmette-Guérin (BCG) could be recommended as adjuvant treatment for intermediate-risk superficial bladder tumors, Spanish researchers say.

ROBOTIC RADICAL cystectomy (RC) may offer advantages over open surgery without compromising pathologic measures of early oncologic efficacy, researchers suggest.

TWICE AS many men as women are treated for bladder cancer, according to a study.